Igc Pharma Inc (IGC) Stock Price, Quote & News

Company Profile

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease in India, the United States, and Colombia. The company's lead product is IGC-AD1, which is in Phase 2 clinical trial for the treatment of agitation in dementia due to Alzheimer's; and TGR-63, IGC-M3, and LMP that are in pre-clinical stage for the treatment of Alzheimer's disease. It also develops IGC-1A and IGC-1C which are in pre-clinical stage for the treatment of metabolic disor...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 983 0998

Website: igcpharma.com

Address:

10224 Falls Road, Potomac, United States

Bcscoatings Jul. 28 at 11:24 PM

$TNFA a lot of attention coming here👀👀👀🔥🔥. $SMX $QH $IGC

0 · Reply

Tom678 Jul. 28 at 8:45 PM

$IGC

0 · Reply

Bulltrader988 Jul. 28 at 6:02 PM

$IGC ...👃👀

0 · Reply

oii Jul. 28 at 11:25 AM

$IGC waiting for the real push

0 · Reply

Bulltrader988 Jul. 27 at 6:23 PM

$IGC begin today: "...today announced the presentation of three scientific posters at the 2025 Alzheimer's Association International Conference ("AAIC"), taking place July 27-31 in Toronto, Canada.... We are excited to share our latest AI innovations at AAIC 2025, which underscore IGC's commitment to transforming Alzheimer's care and research", said Ram Mukunda, CEO of IGC Pharma. "Our cutting-edge deep learning techniques are designed to expand access to earlier diagnosis and accelerate the discovery of effective therapeutics by leveraging diverse, real-world datasets. Showcasing this research at the AAIC is a pivotal step as we establish IGC as a leader in applying AI to precision medicine in Alzheimer's, strengthening our scientific foundation and streamlining drug development..." 👃👀

0 · Reply

billionaire128 Jul. 26 at 8:28 PM

$IGC sleeper trade and sleeper play

0 · Reply

Bulltrader988 Jul. 26 at 6:43 PM

$IGC next week 👃👀

0 · Reply

Ottersberger Jul. 25 at 5:37 PM

$IGC hopefully not tooooooooo long 🤑

0 · Reply

Tom678 Jul. 25 at 1:51 PM

$IGC holding this gem long too.

1 · Reply

UCIdidmyDD Jul. 25 at 4:18 AM

$IGC long 50k

0 · Reply

IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025

Jul 21, 2025, 9:00 AM EDT - 8 days ago

IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards

Jul 10, 2025, 3:10 PM EDT - 19 days ago

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection

Jun 30, 2025, 9:00 AM EDT - 4 weeks ago

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

Jun 27, 2025, 8:30 AM EDT - 4 weeks ago

IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025

Jun 23, 2025, 8:30 AM EDT - 5 weeks ago

IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon

May 22, 2025, 9:30 AM EDT - 2 months ago

IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market

May 12, 2025, 9:30 AM EDT - 2 months ago

IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting

Apr 24, 2025, 9:30 AM EDT - 3 months ago

IGC Pharma Welcomes Strategic Investment from Advisors

Apr 21, 2025, 9:30 AM EDT - 3 months ago

IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs

Apr 8, 2025, 9:30 AM EDT - 4 months ago

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

Apr 1, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

Mar 26, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

Mar 20, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

Mar 17, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida

Mar 12, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock.

Mar 10, 2025, 9:00 AM EDT - 5 months ago

IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results"

Mar 4, 2025, 9:00 AM EST - 5 months ago

IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection

Feb 20, 2025, 9:00 AM EST - 5 months ago

IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market

Feb 18, 2025, 8:30 AM EST - 5 months ago

IGC Pharma Reports Third Quarter Fiscal 2025 Results

Feb 11, 2025, 8:30 AM EST - 6 months ago

IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)

Jan 28, 2025, 8:30 AM EST - 6 months ago

IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease

Jan 13, 2025, 8:30 AM EST - 7 months ago

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

Jan 8, 2025, 8:30 AM EST - 7 months ago

IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy

Dec 19, 2024, 7:00 PM EST - 7 months ago

IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025

Dec 2, 2024, 8:30 AM EST - 8 months ago

IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology

Nov 25, 2024, 8:30 AM EST - 8 months ago

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

Nov 14, 2024, 8:30 AM EST - 9 months ago

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline

Nov 6, 2024, 8:30 AM EST - 9 months ago

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer's and Weight Loss Therapies

Oct 17, 2024, 8:30 AM EDT - 10 months ago

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1

Oct 3, 2024, 9:00 AM EDT - 10 months ago

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge

Sep 18, 2024, 8:00 AM EDT - 11 months ago

IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment

Sep 4, 2024, 8:00 AM EDT - 11 months ago

IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease

Aug 22, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease

Aug 8, 2024, 9:30 PM EDT - 1 year ago

IGC Pharma Reports First Quarter Fiscal 2025 Results

Jul 18, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target

Jul 9, 2024, 9:10 AM EDT - 1 year ago

Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile

Jun 25, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease

Jun 10, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol

May 28, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1

May 21, 2024, 2:00 PM EDT - 1 year ago

IGC Pharma to Attend BIO International Convention 2024

Apr 16, 2024, 7:00 AM EDT - 1 year ago

IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two

Apr 9, 2024, 9:00 AM EDT - 1 year ago

IGC Pharma Adds Advisor in Artificial Intelligence

Mar 26, 2024, 3:00 PM EDT - 1 year ago

IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock

Mar 20, 2024, 11:00 AM EDT - 1 year ago

IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation

Mar 20, 2024, 7:00 AM EDT - 1 year ago

IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024

Mar 12, 2024, 3:00 PM EDT - 1 year ago

IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer's Pipeline

Feb 23, 2024, 12:01 PM EST - 1 year ago

IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target

Feb 16, 2024, 7:05 PM EST - 1 year ago

IGC Pharma Reports Third Quarter Fiscal 2024 Results

Feb 1, 2024, 9:20 AM EST - 1 year ago

IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model

Bcscoatings Jul. 28 at 11:24 PM

$TNFA a lot of attention coming here👀👀👀🔥🔥. $SMX $QH $IGC

0 · Reply

Tom678 Jul. 28 at 8:45 PM

$IGC

0 · Reply

Bulltrader988 Jul. 28 at 6:02 PM

$IGC ...👃👀

0 · Reply

oii Jul. 28 at 11:25 AM

$IGC waiting for the real push

0 · Reply

Bulltrader988 Jul. 27 at 6:23 PM

0 · Reply

billionaire128 Jul. 26 at 8:28 PM

$IGC sleeper trade and sleeper play

0 · Reply

Bulltrader988 Jul. 26 at 6:43 PM

$IGC next week 👃👀

0 · Reply

Ottersberger Jul. 25 at 5:37 PM

$IGC hopefully not tooooooooo long 🤑

0 · Reply

Tom678 Jul. 25 at 1:51 PM

$IGC holding this gem long too.

1 · Reply

UCIdidmyDD Jul. 25 at 4:18 AM

$IGC long 50k

0 · Reply

Bulltrader988 Jul. 24 at 6:29 PM

$IGC "...today announced the presentation of three scientific posters at the 2025 Alzheimer’s Association International Conference (“AAIC”), taking place July 27-31 in Toronto, Canada. The poster presentations highlight advancements in the Company’s proprietary artificial intelligence (“AI”) platforms designed to accelerate drug discovery and improve early detection of Alzheimer’s disease, particularly in low-resource settings.... At the AAIC 2025, IGC’s team will present: Poster Number: 108625 Title: Multimodal Interpretable Transformer for AD (MINT-AD) Poster Number: 108631 Title: MINT-AD: Early Prediction of MMSE & CSI-D Scores with AI Poster Number: 108629 Title: AI in the Drug Discovery Pipeline.." 👃👀 https://igcpharma.com/igc-pharma-to-present-advanced-ai-platforms-for-alzheimers-disease-at-the-aaic-2025/

0 · Reply

angel6 Jul. 24 at 5:13 PM

$IGC give us an actual news like FDA approval

0 · Reply

IGC Jul. 24 at 4:01 PM

$IGC IGC Pharma will present 3 scientific posters at the Alzheimer's Association® International Conference 2025, highlighting our artificial intelligence achievements in Alzheimer’s research. Our presentations explore how AI can support earlier detection, identify high-value clinical opportunities, and streamline drug discovery for underserved and low-resource populations. Authored by our international research team: • Poster 108629 – Néstor González, Paola Ruiz Puentes, Diego Rodríguez-Soacha, Daniel Andrés Crovo Pérez, Ram Mukunda • Poster 108625 – Paola Ruiz Puentes, Néstor González, Daniel Andrés Crovo Pérez, Maria Catalina Ibañez Piñeres, Pablo Arbelaez, Ram Mukunda • Poster 108631 – Daniel Andrés Crovo Pérez, Paola Ruiz Puentes, Néstor González, Pablo Arbelaez, Ram Mukunda We’re honored to contribute to the world’s largest dementia research forum and to continue advancing innovation in neurodegeneration. Read more: https://igcpharma.com/igc-pharma-to-present-advanced-ai-platforms-for-alzheimers-disease-at-the-aaic-2025/

0 · Reply

oii Jul. 24 at 3:43 PM

$IGC lets move

0 · Reply

NVDAMillionaire Jul. 23 at 4:57 PM

$IGC Great piece that accurately captures IGC's current position. So if you want to refresh your understanding of IGC or learn about IGC for the first time, this is essential reading. https://beyondspx.com/article/igc-pharma-revolutionizing-alzheimer-s-diagnostics-and-treatment-with-ai-powered-innovation-nyse-igc

0 · Reply

Lloydclat Jul. 23 at 4:22 PM

$IGC

0 · Reply

Bulltrader988 Jul. 23 at 1:27 PM

$IGC "...today announced the presentation of three scientific posters at the 2025 Alzheimer's Association International Conference ("AAIC"), taking place July 27-31 in Toronto, Canada. The poster presentations highlight advancements in the Company's proprietary artificial intelligence ("AI") platforms designed to accelerate drug discovery and improve early detection of Alzheimer's disease, particularly in low-resource settings. IGC Pharma's team will be participating in person..." 👃👀 https://www.stocktitan.net/news/IGC/igc-pharma-to-present-advanced-ai-platforms-for-alzheimer-s-disease-i5upvjh8efwt.html

0 · Reply

Tom678 Jul. 23 at 1:16 PM

IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025 $IGC amazing news !! Company is growing every day towards success https://www.accessnewswire.com/newsroom/en/biotechnology/igc-pharma-to-present-advanced-ai-platforms-for-alzheimers-disease-at-the-aaic-2025-1051802

0 · Reply

lecorb Jul. 23 at 1:11 PM

$IGC IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025 Wednesday, 23 July 2025 09:00 AM

0 · Reply

lecorb Jul. 23 at 1:10 PM

$IGC https://www.accessnewswire.com/newsroom/en/biotechnology/igc-pharma-to-present-advanced-ai-platforms-for-alzheimers-disease-at-the-aaic-2025-1051802

0 · Reply

RocketQueen Jul. 23 at 12:23 PM

$IGC refreshing fundamentals here. I've been following this since 2018. It looks like things are looking up.

0 · Reply

Tom678 Jul. 23 at 11:27 AM

$IGC

0 · Reply

Market Cap	29.18M
Revenue (ttm)	1.27M
Net Income (ttm)	-7.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-560.63%
Debt to Equity Ratio	0.02

Volume	476,984
Avg Vol	3,166,354
Day's Range	N/A - N/A
Shares Out	79.69M
Stochastic %K	63%
Beta	1.45
Analysts	Sell
Price Target	$3.88